Elsevier

Oral Oncology

Volume 132, September 2022, 105946
Oral Oncology

Letter to the editor
ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib

https://doi.org/10.1016/j.oraloncology.2022.105946Get rights and content

Section snippets

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References (4)

There are more references available in the full text version of this article.

Cited by (1)

View full text